Eric Dobmeier has served as a member of our board of directors since September 2016. From January 2018 to June 2018, Eric served as President and Chief Executive Officer of Silverback Therapeutics, Inc. and from 2002 to 2017, Eric held positions of increasing responsibility at Seattle Genetics, Inc., a public biotechnology company, most recently as Chief Operating Officer from June 2011 to December 2017. Prior to joining Seattle Genetics, Eric was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric currently serves on the board of directors of Atara Biotherapeutics, Inc., a publicly-traded biotechnology company. He holds a JD from University of California, Berkeley School of Law and an AB in History from Princeton University.